Genomic Alterations in Advanced Esophageal Cancer May Lead to Subtype-Specific Therapies
Authors:
Open Access
- 1 July 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 18 (7) , 823-832
Abstract
The development of targeted agents for metastatic esophageal or gastroesophageal junction (GEJ) tumors has been limited when compared with that for other common tumors. To date, the anti-human epidermal growth factor receptor-2 (HER-2) antibody, trastuzumab, in combination with chemotherapy, is the only approved novel agent for these cancers, and its use is limited to the small population of patients whose tumors overexpress HER-2. Despite recent progress in the field, median overall survival remains only 8–12 months for patients with stage IV esophageal or GEJ cancer. In this article, we examine the molecular aberrations thought to drive the development and spread of esophageal cancer and identify promising targets for specific tumor inhibition. Data from clinical studies of targeted agents are reviewed, including epidermal growth factor receptor antibodies, tyrosine kinase inhibitors, HER-2, and vascular endothelial growth factor-directed therapy. Current and future targets include MET, fibroblast growth factor receptor, and immune-based therapies. Evidence from trials to date suggests that molecularly unselected patient cohorts derive minimal benefit from most target-specific agents, suggesting that future collaborative investigation should focus on preselected molecular subgroups of patients with this challenging heterogeneous disease.Keywords
This publication has 64 references indexed in Scilit:
- Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and OncogenesisCancer Research, 2012
- Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414)Journal of Thoracic Oncology, 2012
- FGFR2 gene amplification and clinicopathological features in gastric cancerBritish Journal of Cancer, 2012
- Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junctionBritish Journal of Cancer, 2011
- HER2 amplification, overexpression and score criteria in esophageal adenocarcinomaLaboratory Investigation, 2011
- A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagusCancer, 2010
- Cetuximab as Second-Line Therapy in Patients with Metastatic Esophageal Adenocarcinoma: A Phase II Southwest Oncology Group Study (S0415)Journal of Thoracic Oncology, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Association Studies of CYP1A1 and GSTM1 Polymorphisms with Esophageal Cancer Risk: Evidence-based Meta-analysesArchives of Medical Research, 2009
- Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinomaBritish Journal of Cancer, 2008